Search Results - "Bray, Victoria Jane"

The prognostic influence of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in stage III non-small cell lung cancer (NSCLC) treated with consolidation durvalumab by Nindra, Udit, Shahnam, Adel, Stevens, Samuel Xavier, Pal, Abhijit, Yip, Po Yee, Adam, Tamiem, Lee, Jenny HJ, Boyer, Michael J., Nagrial, Adnan, Kao, Steven Chuan-Hao, Bray, Victoria Jane

“…e18773 Background: The neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) has been of prognostic interest in lung cancer. Sustained…”
Get full text

The influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab by Nindra, Udit, Stevens, Samuel Xavier, Shahnam, Adel, Pal, Abhijit, Adam, Tamiem, Yip, Po Yee, Lee, Jenny HJ, Boyer, Michael J., Nagrial, Adnan, Kao, Steven Chuan-Hao, Bray, Victoria Jane

“…e18810 Background: The PACIFIC trial established concurrent chemoradiation followed by one year of consolidation durvalumab as the standard of care for…”
Get full text

Effect of delayed consolidation durvalumab and timing of treatment on survival outcomes in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT) by Stevens, Samuel Xavier, Nindra, Udit, Shahnam, Adel, Bray, Victoria Jane, Yip, Po Yee, Adam, Tamiem, Lee, Jenny HJ, Boyer, Michael J., Nagrial, Adnan, Kao, Steven Chuan-Hao

“…e18809 Background: Consolidation treatment with durvalumab following CRT is now standard of care for pts with unresectable stage III NSCLC. In PACIFIC,…”
Get full text

Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer by Osei-Fofie, Daniel, Wetter, Julie, Landers, Greg A., Kraus, Peter Alfred, Sukumaran, Shawgi, Mun, Hui, Stein, Brian N., Bray, Victoria Jane, Framroze, Bomi, Gelfand, Jeffrey, Song, Paul Y., Lategan, Andries, Dimitriu, Mikaela, Sonis, Stephen T.

“…Abstract only 6075 Background: OM is a common, painful, and costly toxicity associated with cytotoxic regimens used to treat H&N cancers, which may result in…”
Get full text